ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Diisopropylethylamine → N-[((1S,4S,6S)-3-{[6-methyl-3-(1H-pyrazol-1-yl)-2-pyridinyl]carbonyl}-3-azabicyclo[4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyrazinamine

HRID 1094780
印刷

反応式

HRID 1094780 の反応式
[CH3:1][C:2]1[N:7]=[C:6]([C:8]([OH:10])=O)[C:5]([N:11]2[CH:15]=[CH:14][CH:13]=[N:12]2)=[CH:4][CH:3]=1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.CCN(C(C)C)C(C)C.[C@H:47]12[CH2:53][C@H:52]1[CH2:51][C@@H:50]([CH2:54][NH:55][C:56]1[CH:61]=[N:60][C:59]([C:62]([F:65])([F:64])[F:63])=[CH:58][N:57]=1)[NH:49][CH2:48]2.C([O-])(O)=O.[Na+]>CN(C=O)C>[CH3:1][C:2]1[N:7]=[C:6]([C:8]([N:49]2[C@H:50]([CH2:54][NH:55][C:56]3[CH:61]=[N:60][C:59]([C:62]([F:65])([F:63])[F:64])=[CH:58][N:57]=3)[CH2:51][C@H:52]3[C@H:47]([CH2:53]3)[CH2:48]2)=[O:10])[C:5]([N:11]2[CH:15]=[CH:14][CH:13]=[N:12]2)=[CH:4][CH:3]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 5

HCID 81531DiisopropylethylamineHCID 516892Sodium BicarbonateHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 593636726-Methyl-3-(1H-pyrazol-1-yl)picolinic acidHCID 59396007N-[(1S,4S,6S)-3-azabicyclo[4.1.0]hept-4-ylmethyl]-5-(trifluoromethyl)-2-pyrazinamine

生成物 1

HCID 46221270
N-[((1S,4S,6S)-3-{[6-methyl-3-(1H-pyrazol-1-yl)-2-pyridinyl]carbonyl}-3-azabicyclo[4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyrazinamine

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒2 回

実験手順

6-methyl-3-(1H-pyrazol-1-yl)-2-pyridinecarboxylic acid D38 (24.63 mg) was dissolved in 1 ml of DMF, then TBTU (46.0 mg, 0.143 mmol) and DIPEA (0.025 ml, 0.143 mmol) were added. The suspension was stirred for 30 minutes at room temperature. N-[(1S,4S,6S)-3-azabicyclo[4.1.0]hept-4-ylmethyl]-5-(trifluoromethyl)-2-pyrazinamine D31 (30 mg) dissolved in 1 ml of DMF was added and the reaction was stirred overnight at room temperature. NaHCO3 saturated solution were added, and the aqueous layer was extracted with of DCM. The organic layers were collected together, dried through a phase separator and concentrated under vacuum to give a crude which was purified by SCX chromatography (column size 5 g). A second purification was performed by silica —NH chromatography (Biotage SP—column size 11 g, using Cy:EtOAc=5:5 to EtOAc). It was recovered the title compound E5 (22 mg). UPLC: (Acid Final_QC): rt=0.81 and 0.85 minutes (rotamers present), peaks observed: 458 (M+1). C22H22F3N7O requires 457. 1H NMR (400 MHz, CDCl3) δ ppm 8.29 (s, 1 H), 7.85-7.77 (m, 3 H), 7.52 (s, 1 H), 7.38-7.32 (m, 1 H), 7.05-6.89 (m, 1 H) 6.35-6.30 (m, 1 H) 4.58-4.37 (m, 1 H), 3.77-3.66 (m, 1 H), 3.65-3.37 (m, 2 H), 2.65 (s, 3 H), 2.50-2.36 (m, 2 H), 1.42-0.83 (m, 3 H), 0.82-0.71 (m, 1 H), 0.15-0.06 (m, 1 H).

後処理

  1. additionwas added
  2. stirringthe reaction was stirred overnight at room temperature
  3. extractionthe aqueous layer was extracted with of DCM
  4. customThe organic layers were collected together
  5. customdried through a phase separator
  6. concentrationconcentrated under vacuum
  7. customto give a crude which
  8. customwas purified by SCX chromatography (column size 5 g)
  9. customA second purification
  10. customIt was recovered the title compound E5 (22 mg)
  11. customrt=0.81 and 0.85 minutes (rotamers present)

出典と根拠

ORDレコード
ord-be7efe91cd59420485d5dbc606883041
出典データセット
uspto-grants-2012_03
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08133908B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート